Janelle Hart


Advancing the Perioperative Management of Bladder Cancer

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Rachel V. Rose, JD, MBA


Key Telehealth Factors to Monitor

When providing telehealth, providers must check individual state laws and policies regarding telehealth and providing telehealth across state lines. In sum, there is a lot to stay on top of in relation to telehealth.

Darlene Dobkowski


Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study Shows

Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.

Guenther Koehne, MD, PhD


What’s Next in Regard to Advances in Treating Hematologic Malignancies?

Gunther Koehne, MD, PhD, discusses his hopes for future advances for patients with hematologic malignancies.

Robert Galamaga, DO


Kidney Cancer Awareness Month: The Evolving Landscape of RCC Management

Robert Galamaga, DO, reviews single-agent and combination targeted therapy advances in renal cell carcinoma for Kidney Cancer Awareness Month.

Uday R. Popat, MD


Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHD

Uday R. Popat, MD, discusses the role of ruxolitinib as treatment of patients with graft-versus-host-disease.

Justin M. Watts, MD


Pevonedistat/Azacitidine Combo Demonstrates Encouraging EFS Data in Phase 2 Trial in MDS

Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.

Sachin Gupta


Solutions Are Emerging to Help MIDs Efficiently Manage Prior Authorizations

Medically integrated dispensing pharmacies in oncology often deal with complex PAs that can inhibit delivery of timely, quality care and consume staff resources.

Samer A. Srour, MD, MS


Overcoming Challenges With Use of CAR T-Cell Therapy in Solid Tumors

Samer A. Srour, MD, explains the history of researching chimeric antigen receptor T-cell therapy in solid tumors.

Alexander Spira, MD, PhD


Amivantamab and Lazertinib as a Potential Option for EGFR-Mutant NSCLC

Alexander Spira, MD, PhD, FACP, discusses osimertinib-relapsed disease and its sensitivity to EGFR or MET inhibition.

Kristina Mirabeau-Beale, MD, MPH


Breast Cancer Awareness Month: What to Know for Different Types of Breast Cancer

For Breast Cancer Awareness Month Kristina Mirabeau-Beale, mD, MPH, and Bridget Koontz, MD, discuss the different types of breast cancer that clinicians need to be aware of.

Kaveh Zakeri, MD, MAS


JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.

Jen Buhay, PhD


Precision Medicine Will Drive New Standards of Care in the Post–COVID-19 World

Once the impact of COVID-19 begins to minimize and activities settle into a “new normal,” efforts to expand precision medicine across many diseases will resume.

Ronald L. Paquette, MD


The Role of Age in Bone Marrow and Stem Cell Transplants for MDS

Ronald L. Paquette, MD, discusses how age impacts the use of bone marrow and stem cell transplants in patients with myelodysplastic syndrome.

Matthew Lunning, DO, FACP


Unmet Needs and Future Directions for Patients with R/R DLBCL

Dr Matthew Lunning closes his discussion on DLBCL by highlighting unmet needs in the treatment landscape.

Sheela Tejwani, MD


Recent Advances in mCSPC and Advice for Community Oncologists

Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.

David Dingli, MD, PhD


Dingli Compares Trial Data and Recent ASH Updates in the Newly Diagnosed Multiple Myeloma Landscape

The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.

Rafael Fonseca, MD


Evolving Treatment Options for Transplant-Ineligible Multiple Myeloma

Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.

Manali Kamdar, MD, MBBS


Novel Anti-CD19 CAR T-Cell Therapy Shows Efficacy in Multiple BCL Subtypes

Manali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.

Anne Chiang, MD


Considering Mutations and Resistance in Lung Cancer to Improve Precision Medicine

Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses hard-to-treat lung cancer and how due to recent lung cancer innovations and treatment options, the tumor is becoming increasingly heterogeneous. 

Eric Nadler, MD, MDD


Real-World Implications of the IMpower133 Trial in ES-SCLC

Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.

Lindsay Fischer


Study Shows Feasibility of Using Exome Sequencing to Conduct CDCT1 Genetic Condition Screening

Whole-exome sequencing demonstrated the ability to identify genetic conditions in patients for whom clinical guidelines did not require testing.

Mitul Gandhi, MD


Exploring Current and Future Treatment in Patients With DLBCL

Mitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.

Jared Crumb, PharmD


Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With Abemaciclib

Dose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.

Aaron Farberg, MD


Risk Information Can Influence Clinical Decision-Making in Melanoma

Cutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.

Kenneth C. Anderson, MD


Multiple Myeloma Treatment Paradigm Improved Markedly In Recent Years

Kenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.